Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
279actual
Sites
86
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-24 | actual | When the study began enrolling |
| Primary completion | 2025-11-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-23 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Psoriatic Arthritis
- Obesity
Interventions
- Drug: Ixekizumab — also filed as LY2439821
- Drug: Tirzepatide — also filed as LY3298176
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction
measured Baseline up to Week 36
Publications
- PMID 41903163 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed